UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Management Meeting Reinforces Improving Outlook
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $145.74 +0.67%
Rating Summary:
16 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
16 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
UBS maintains a 'Buy' on Johnson & Johnson (NYSE: JNJ) price target lowered from $72 to $69.
UBS analyst says, "We had an opportunity to meet w/ CFO Dominic Caruso & Vice Chairman Sheri McCoy. On our estimates, we bumped ’12 & ’13 EPS modestly by $0.02 to $5.19 (+4%) & $5.67 (+9%) as we now assume significant share repo to offset SYST issuance (Street: $5.24 & $5.63). Further, mgmt seemed more upbeat on ’12 margin expansion. We continue to model improving organic rev growth on Pharma new products & Consumer re-launches (~2.5% in ’11; ~4% in ’12; ~5.5% in ’13)."
"Returning to a margin expansion outlook - Pharma will be the strongest driver; launch expenses to persist but incremental spend will be less than sales growth. Consumer more or less as re-investment behind re-launched brands may be needed. Despite headwinds on price & volumes, MD&D will benefit from a major reorganization into 3 broad op groups while benefits from supply chain initiatives also play out. Including SYST, we model 60 / 110bps of op mgn expansion in ’12 / ’13 (40 / 70bps ex-SYST)."
For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.
Shares of Johnson & Johnson closed at $64.53 yesterday.
UBS analyst says, "We had an opportunity to meet w/ CFO Dominic Caruso & Vice Chairman Sheri McCoy. On our estimates, we bumped ’12 & ’13 EPS modestly by $0.02 to $5.19 (+4%) & $5.67 (+9%) as we now assume significant share repo to offset SYST issuance (Street: $5.24 & $5.63). Further, mgmt seemed more upbeat on ’12 margin expansion. We continue to model improving organic rev growth on Pharma new products & Consumer re-launches (~2.5% in ’11; ~4% in ’12; ~5.5% in ’13)."
"Returning to a margin expansion outlook - Pharma will be the strongest driver; launch expenses to persist but incremental spend will be less than sales growth. Consumer more or less as re-investment behind re-launched brands may be needed. Despite headwinds on price & volumes, MD&D will benefit from a major reorganization into 3 broad op groups while benefits from supply chain initiatives also play out. Including SYST, we model 60 / 110bps of op mgn expansion in ’12 / ’13 (40 / 70bps ex-SYST)."
For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.
Shares of Johnson & Johnson closed at $64.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Johnson & Johnson (JNJ) to Buy, 'Steady outlook, low expectations'
- Johnson & Johnson (JNJ) PT Lowered to $176 at DZ Bank
- Equifax (EFX) PT Raised to $240 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
